Abstract: A marker having excellent sensitivity and specificity to pancreatic cancer and intraductal papillary mucinous neoplasms. Also, a kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms to detect the marker, and a method for evaluating a metastasis of a pancreas cancer cell by using the marker. The marker for pancreatic cancer and intraductal papillary mucinous neoplasms according to the present invention comprises one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein. The kit for diagnosing pancreatic cancer and intraductal papillary mucinous neoplasms according comprises an antibody to one or more proteins selected from the group essentially consisting of secretoglobin, family 1D, member 2 and podocalyxin-like protein.
Type:
Grant
Filed:
November 22, 2016
Date of Patent:
August 30, 2022
Assignee:
NATIONAL UNIVERSITY CORPORATION KOCHI UNIVERSITY
Abstract: The present invention provides genetic tags operably linked to transgenes. The expression of the genetic tag allows identification, detection, selection, and ablation of cells expressing the transgene and the genetic tag. In some alternatives the genetically modified host cell comprises a transgene comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain and a polynucleotide coding for a genetic tag.
Abstract: The present application provides a bispecific antibody or an antibody mixture with common light chains and a preparation method therefor. the present application also provides a nucleic acid molecule encoding the antibody or the mixture, a recombinant vector and a recombinant cell comprising the nucleic acid molecule, as well as a detection and quantitation method for the antibody or the mixture.
Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize human mesothelin582-598 (IP-NGYLVLDLSMQEALS) (SEQ ID NO: 1) are disclosed. Anti-mesothelin binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are disclosed. Methods of reducing mesothelin shed from cell membranes, methods of reducing the activity of TNF? converting enzyme, methods of detecting the presence of cancer, and methods of treating or preventing cancer are also disclosed.
Type:
Grant
Filed:
May 17, 2018
Date of Patent:
July 19, 2022
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Ira H. Pastan, Masanori Onda, Tapan Bera, Mitchell Ho
Abstract: The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns re-combinant polypeptides and uses thereof.
Abstract: This invention relates to anti-LAG-3 antibodies and methods of using them in treating diseases and conditions that benefit from modulating LAG-3 activity, e.g., cancer.
Type:
Grant
Filed:
October 13, 2017
Date of Patent:
July 19, 2022
Assignee:
Symphogen A/S
Inventors:
Michael Monrad Grandal, Vikram Kjøller Bhatia, Torben Gjetting, Camilla Fröhlich, Gunther Roland Galler, Michael Kragh, Ivan David Horak, Thomas Bouquin, Mikkel Wandahl Pedersen
Abstract: The invention provides novel anti-BTLA antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
Type:
Grant
Filed:
March 31, 2020
Date of Patent:
July 12, 2022
Assignees:
Curia IP Holdings, LLC, TRIANNI, Inc.
Inventors:
Brian A. Zabel, John A. Lippincott, Yayue Zheng, Megha Vaman Rao, Miao Tan, David P. Meininger
Abstract: The present disclosure relates to compositions and methods of killing cells. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
Type:
Grant
Filed:
November 25, 2019
Date of Patent:
June 21, 2022
Assignee:
THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
Abstract: The present disclosure relates to compositions and methods of killing cells in vitro or in vivo. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein. In particular examples the antibody recognizes a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm?2, thereby killing the cell. Also provided are wearable devices that include an article of clothing, jewelry, or covering; and an NIR LED incorporated into the article, which can be used with the disclosed methods.
Type:
Grant
Filed:
November 26, 2019
Date of Patent:
June 21, 2022
Assignee:
THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
Abstract: An agonistic 4-1BB monoclonal antibody or an antigen binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: a CDR1 region having an amino acid sequence as shown in SEQ ID NO: 1, a CDR2 region having an amino acid sequence as shown in SEQ ID NO: 2, and a CDR3 region having an amino acid sequence as shown in SEQ ID NO: 3, the light chain variable region comprising: a CDR1 region having an amino acid sequence as shown in SEQ ID NO: 4, a CDR2 region having an amino acid sequence as shown in SEQ ID NO: 5, and a CDR3 region having an amino acid sequence as shown in SEQ ID NO: 6. The monoclonal antibody is targeted towards h4-1BB, and specifically binds to h4-1BB to activate T cells for treatment of a variety of cancers.
Abstract: Methods are provided for determining prognosis of multiple myeloma in a patient by measuring expression of BCMA in a sample. Also provided are methods for treating multiple myeloma by measuring expression of BCMA in a sample and administering an effective amount of an antigen binding protein that binds BCMA. Also provided are kits for measuring BCMA expression in a sample.
Type:
Grant
Filed:
October 28, 2016
Date of Patent:
June 7, 2022
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Danton Bounds, Jenny L. Craigen, William E. Fieles, Fiona M. Germaschewski, Gaelle Herledan, Lydia Lee, Patrick A. Mayes, Lee McCahon, Katherine (Nee Sully) Nevin, Jennifer Paterson, Manuel Rodriguez-Justo, Laura M. Seestaller-Wehr, James Tunstead, Kwee L. Yong
Abstract: The present document describes a method of inhibiting cancer tumor growth in a patient in need thereof, comprising at least a first treatment comprising steps a) and b): a) administering to the patient an immune adjuvant in combination with a therapeutic monoclonal antibody specific for a tumor associated antigen; and b) administering to the patient the immune adjuvant; and a final treatment consisting of administering to the patient the therapeutic monoclonal antibody specific for a tumor associated antigen, wherein time between step a) and step b) is a time sufficient for treatment of the patient with the immune adjuvant, and wherein time between the step b) and the final treatment is from about 10 to about 14 weeks.
Type:
Grant
Filed:
December 3, 2019
Date of Patent:
June 7, 2022
Assignee:
Oncoquest Inc.
Inventors:
Christopher F. Nicodemus, Ragupathy Madiyalakan
Abstract: The present invention relates to the use of an inhibitor of HER-3 for the treatment of a hyperproliferative disease in combination with radiation treatment.
Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly colorectal, ovarian (e.g., platinum-resistant ovarian), pancreatic, and endometrial cancers. Also provided are methods, compositions, and kits for treatment of tumors or cancer using combinations that include a VEGF/DLL4 bispecific agent and one or more chemotherapeutic agents (e.g., leucovorin, 5-fluorouracil, and irinotecan; paclitaxel; gemcitabine and ABRAXANE® (albumin-bound paclitaxel for injectable suspension); and paclitaxel and carboplatin). The present invention further provides methods of using the agents or combinations of agents to inhibit growth of a colorectal, ovarian, pancreatic, or endometrial tumor.
Type:
Grant
Filed:
September 23, 2016
Date of Patent:
May 24, 2022
Assignee:
MEREO BIOPHARMA 5, INC.
Inventors:
Jakob Dupont, Hema Parmar, Robert Joseph Stagg
Abstract: The present invention provides methods of preventing or reducing the risk of recurrence of endometrial and ovarian cancers which express low levels of folate binding protein (FBP) by administration of a vaccine containing an E39 peptide.
Type:
Grant
Filed:
January 16, 2018
Date of Patent:
May 24, 2022
Assignee:
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
Abstract: Disclosed are a bispecific antigen-binding construct and the preparation method and use thereof, wherein the construct comprises a first antigen binding unit and a second antigen binding unit, the first antigen binding unit is a single chain variable region antibody fragment ScFV which specifically binds to the surface antigen of immune cells, and the second antigen binding unit is a Slit2D2 protein fragment which specifically binds to the surface antigen Robo1 of tumour cells. That is to say, the construct can bind to the surface antigen of immune cells and the surface Robo1 molecule of tumour cells at the same time, so that as the distance between tumour cells and immune cells get smaller, the quiescent immune cells are effectively activated, and the effect of killing and wounding tumours is produced.
Type:
Grant
Filed:
May 11, 2017
Date of Patent:
May 24, 2022
Assignee:
Asclepius (Suzhou) Technology Company Group, Co., Ltd.
Abstract: This disclosure is directed to immune treatment of a disease (e.g., cancer) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain.
Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCS).
Type:
Grant
Filed:
June 14, 2018
Date of Patent:
May 3, 2022
Assignees:
ADC THERAPEUTICS SA, MEDIMMUNE LIMITED
Inventors:
Jay Marshall Feingold, David Rodney Ungar